Cannabis Law Report

AUGUST 10, 2021

As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. Madison Natarajan, MS. – August 5, 2021.

Clinical Trials 105

Clinical Trials Research and Development Therapy Treatment 105

Cannabis Law Report

JULY 19, 2021

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). We don’t want to see research fall to the wayside as it has for cannabis, both in Canada and globally. In Canada, mental health issues affect more than 6.7

Clinical Trials 75

Clinical Trials Research and Development Hybrid Medicine 75

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

DECEMBER 27, 2019

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Veriheal

JULY 16, 2020

The commission tasked with developing recommendations to improve mental health treatment for veterans concluded: Congress and the executive branch need to promote research into the therapeutic potential of cannabis and psychedelics such as psilocybin mushrooms and MDMA. Research is Limited Due to Many Obstacles.

Research and Development 97

Research and Development Clinical Trials Treatment Compliance 97

Cannabis Law Report

AUGUST 13, 2021

Derived from Salvia divinorum, SalA is a unique non-nitrogenous agonist of the kappa-opioid receptor (KOR) with potential use in treatment-resistant depression (TRD), substance use disorder (SUD) and pain. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD. BERLIN, Aug.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Veriheal

AUGUST 28, 2023

This discovery adds to the ongoing research on the medical use of psychedelics in psychiatry. And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. Current approaches to treat this condition are helpful but do not always provide full relief.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

JULY 6, 2021

GH Research, a Dublin-based company studying the potential of 5-MeO-DMT for the treatment of psychiatric and neurological disorders, is now listing its stock on the Nasdaq under the symbol “GHRS” after opening for trading on Friday, July 2 at $22. The financing was co-led by RA Capital and RTW Investments, LP, U.S.

Clinical Trials 74

Clinical Trials Research and Development Treatment Therapy 74

Cannabis Law Report

JULY 28, 2021

Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options. Advance to FDA IND-enabling studies to support human clinical studies. Previously the Company announced that it had secured FDA Orphan Drug Designation for cepharanthine in the treatment of esophageal cancer.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Project CBD

NOVEMBER 11, 2023

NM: As someone who has been researching cannabis for decades, how do you feel about the current legalization situation worldwide and in Japan, in particular? Dr. Andrew Weil: I think the trend very clearly is that in most developed countries, cannabis is being made legal first for medical uses and then also for recreational uses.

Medicine 306

Medicine Research and Development Pharmaceutical Cannabis 306

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Silo Pharma Inc. Looking to the Future.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I firmly believe the current downtrend in the industry is an overreaction to incredibly positive results from Compass Pathways 2b trial, which have clearly been misinterpreted. DENVER, Dec. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JULY 6, 2021

This collaboration is intended to include research into COMP360 psilocybin therapy and other novel therapies that may be developed by COMPASS in areas of unmet need such as depression, post-traumatic stress disorder (PTSD) and anorexia. This is a really exciting prospect and has the potential to change people’s lives for the better.”.

Research and Development 76

Research and Development Clinical Trials Therapy Patients 76

Cannabis Law Report

MARCH 30, 2019

Ministry of Health, Labor and Welfare officials recently announced the trials during a meeting of the Okinawa-Northern Task Force, a research and development agency. Epidiolex was crafted as a treatment for two forms of childhood epilepsy. Japanese officials approve Epidiolex for clinical trials.

Clinical Trials 45

Clinical Trials Research and Development Epilepsy Environment 45

Cannabis Law Report

SEPTEMBER 10, 2021

The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. Clerkenwell Health is a psychedelic specialist clinical research organisation, based in the UK, backed with investment from VC Fund Vine Ventures, and Angel investors.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Puff Puff Post

JANUARY 1, 2020

As cannabis legalisation spreads, research has found considerable use in for cannabis in medicine. One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids.

Treatment 49

Treatment Clinical Trials Research and Development Cannabinoids 49

Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. It is our hope that this study may embolden clinicians and patients to effectively partner in considering these treatments.”.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

CannaMD

APRIL 23, 2020

For those unfamiliar, GB Sciences is a technology company that merges plant biology, cultivation, and post-production processes in order to optimize safe, consistent medical cannabis treatment. They describe their goal as “marrying cutting edge cannabis cultivation with biopharmaceutical research and development.”

Clinical Trials 116

Clinical Trials Research and Development Marijuana Treatment 116

Cannabis Law Report

AUGUST 2, 2021

capital markets, negative global economic conditions, potential negative developments in our clinical trials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. About Bionomics Limited. The post Bionomics Announces Plans to Conduct U.S.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

AUGUST 22, 2021

The addition of methylated tryptamines with pending patent protection is focused on the potential improvement of treatments for mental health conditions including depression, anxiety and addiction, as well as other psychological and neurologic conditions. .” ” About PsyBio Therapeutics Corp.

Clinical Trials 98

Clinical Trials Research and Development Treatment Conditions 98

Cannabis Law Report

JULY 24, 2021

At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. “At At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

AUGUST 10, 2021

(“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

SEPTEMBER 2, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. Prohibition Partners has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which will probably have a large impact on the medicinal cannabis space.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

AUGUST 9, 2021

Investors will continue to keep an eye on several ongoing clinical trials, as well as private companies that are gearing up to go public over the coming quarters. NEO: MEDI) (OTC: KONEF) signed an exclusive agreement for the use of VR technology in psychedelic treatments with OVR Tech LLC. Industry Developments.

Clinical Trials 105

Clinical Trials Decriminalization Research and Development Treatment 105

Veriheal

FEBRUARY 9, 2023

Although many rely on imaging scans to diagnose illnesses and get treatment of various kinds, getting into the enclosed chamber can be stressful. Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. There is still much yet to learn about how psilocybin can work in a clinical setting.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Veriheal

JANUARY 28, 2022

A team of researchers at Tel Aviv University in Tel Aviv, Israel, led by Ph.D. The cannabis compound cannabidivarin (CBDV) has already been found to be a promising treatment for ASD, particularly in terms of repetitive behaviors, irritability, social functioning, and inflammation. About the Study: Autism and Cannabis.

Oil 104

Oil THC Research and Development Treatment 104

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain. RYAH Group Inc. The Upshot.

Data 105

Data Clinical Trials Research and Development Indica 105

Veriheal

MAY 16, 2022

Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Specifically, the group focused on ketamine’s ability to relieve the side effects of a common treatment called Levodopa.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. NEO:FH , Forum ), an exclusively natural psychedelic drug development company. per cent to reach US$6.86 billion in 2027, up significantly from $2.07 billion in 2019.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

MMJ Recs

JULY 9, 2024

Traditional treatments, while helpful to some extent, often come with limitations and side effects that can further burden individuals already dealing with a debilitating disease. Medical marijuana has emerged as a promising alternative treatment option for managing symptoms associated with MS.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research. Clinical Trial Sample Size.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98